Raymond James set a $10.00 target price on IMV (NYSE:IMV) in a research report released on Monday morning, BayStreet.CA reports. The firm currently has a market perform rating on the stock.
IMV has been the topic of several other research reports. HC Wainwright started coverage on IMV in a report on Monday, March 25th. They issued a buy rating and a $11.50 price objective on the stock. Zacks Investment Research downgraded IMV from a hold rating to a sell rating in a report on Tuesday, January 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. IMV has an average rating of Hold and a consensus target price of $11.00.
IMV opened at $4.00 on Monday. IMV has a 12 month low of $2.90 and a 12 month high of $7.21.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ipswich Investment Management Co. Inc. purchased a new position in shares of IMV in the fourth quarter worth about $34,000. Morgan Stanley increased its holdings in shares of IMV by 565.3% in the first quarter. Morgan Stanley now owns 25,068 shares of the company’s stock worth $101,000 after buying an additional 21,300 shares during the period. Hartford Financial Management Inc. increased its holdings in IMV by 15.0% during the 4th quarter. Hartford Financial Management Inc. now owns 26,850 shares of the company’s stock valued at $139,000 after purchasing an additional 3,500 shares during the period. Ironwood Investment Management LLC purchased a new position in IMV during the 1st quarter valued at about $135,000. Finally, Bank of Montreal Can increased its holdings in IMV by 18.5% during the 1st quarter. Bank of Montreal Can now owns 75,661 shares of the company’s stock valued at $304,000 after purchasing an additional 11,807 shares during the period.
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Read More: Is the QQQ ETF safe?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.